An emerging role for the miR-26 family in cardiovascular disease

Eapen, 2012, Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward, Circ Cardiovasc Qual Outcomes, 5, 594, 10.1161/CIRCOUTCOMES.112.966150 Goldstein, 2000, Multiple complex coronary plaques in patients with acute myocardial infarction, N Engl J Med, 343, 915, 10.1056/NEJM200009283431303 Milonas, 2010, Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction, Am J Cardiol, 105, 1229, 10.1016/j.amjcard.2009.12.032 Cohn, 2000, Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling, J Am Coll Cardiol, 35, 569, 10.1016/S0735-1097(99)00630-0 Frangogiannis, 2014, The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities, J Cardiovasc Pharmacol, 63, 185, 10.1097/FJC.0000000000000003 Pfeffer, 1985, Influence of chronic captopril therapy on the infarcted left ventricle of the rat, Circ Res, 57, 84, 10.1161/01.RES.57.1.84 Seropian, 2014, Anti-inflammatory strategies for ST-elevation acute myocardial infarction ventricular remodeling, J Am Coll Cardiol, 63, 1593, 10.1016/j.jacc.2014.01.014 Quiat, 2013, MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment, J Clin Invest, 123, 11, 10.1172/JCI62876 Boettger, 2009, Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster, J Clin Invest, 119, 2634, 10.1172/JCI38864 Xin, 2009, MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury, Genes Dev, 23, 2166, 10.1101/gad.1842409 Callis, 2009, MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice, J Clin Invest, 119, 2772, 10.1172/JCI36154 Montgomery, 2011, Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure, Circulation, 124, 1537, 10.1161/CIRCULATIONAHA.111.030932 Thum, 2007, MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure, Circulation, 116, 258, 10.1161/CIRCULATIONAHA.107.687947 van Rooij, 2009, A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance, Dev Cell, 17, 662, 10.1016/j.devcel.2009.10.013 van Rooij, 2006, A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure, Proc Natl Acad Sci U S A, 103, 18255, 10.1073/pnas.0608791103 van Rooij, 2007, Control of stress-dependent cardiac growth and gene expression by a microRNA, Science, 316, 575, 10.1126/science.1139089 Dorn, 2012, A human 3′ miR-499 mutation alters cardiac mRNA targeting and function, Circ Res, 110, 958, 10.1161/CIRCRESAHA.111.260752 Icli B, Wara AK, Moslehi J, et al. 2013. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res. Roy, 2009, MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue, Cardiovasc Res, 82, 21, 10.1093/cvr/cvp015 Shieh, 2011, Alpha-Tomatine suppresses invasion and migration of human non-small cell lung cancer NCI-H460 cells through inactivating FAK/PI3K/Akt signaling pathway and reducing binding activity of NF-kappaB, Cell Biochem Biophys, 60, 297, 10.1007/s12013-011-9152-1 Rodriguez, 2004, Identification of mammalian microRNA host genes and transcription units, Genome Res, 14, 1902, 10.1101/gr.2722704 Saini, 2007, Genomic analysis of human microRNA transcripts, Proc Natl Acad Sci U S A, 104, 17719, 10.1073/pnas.0703890104 Yeo, 2005, Small CTD phosphatases function in silencing neuronal gene expression, Science, 307, 596, 10.1126/science.1100801 Sapkota, 2006, Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways, J Biol Chem, 281, 40412, 10.1074/jbc.M610172200 Wu, 2009, Small C-terminal domain phosphatase enhances snail activity through dephosphorylation, J Biol Chem, 284, 640, 10.1074/jbc.M806916200 Zhu, 2012, MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein, Nucleic Acids Res, 40, 4615, 10.1093/nar/gkr1278 Potente, 2011, Basic and therapeutic aspects of angiogenesis, Cell, 146, 873, 10.1016/j.cell.2011.08.039 Wu, 1998, Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction, Circulation, 97, 765, 10.1161/01.CIR.97.8.765 Falanga, 2005, Wound healing and its impairment in the diabetic foot, Lancet, 366, 1736, 10.1016/S0140-6736(05)67700-8 Zlokovic, 2011, Neurovascular pathways to neurodegeneration in Alzheimer׳s disease and other disorders, Nat Rev Neurosci, 12, 723, 10.1038/nrn3114 Liang, 2007, Characterization of microRNA expression profiles in normal human tissues, BMC Genomics, 8, 166, 10.1186/1471-2164-8-166 Lorell, 2000, Left ventricular hypertrophy: pathogenesis, detection, and prognosis, Circulation, 102, 470, 10.1161/01.CIR.102.4.470 Nishimura, 2003, Cardiology patient page. Hypertrophic cardiomyopathy: a patient perspective, Circulation, 108, e133, 10.1161/01.CIR.0000097621.97566.96 Wei, 2013, NF-kappaB mediated miR-26a regulation in cardiac fibrosis, J Cell Physiol, 228, 1433, 10.1002/jcp.24296 Zhang, 2013, MicroRNA-26 was decreased in rat cardiac hypertrophy model and may be a promising therapeutic target, J Cardiovasc Pharmacol, 62, 312, 10.1097/FJC.0b013e31829b82e6 Liang, 2001, The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo, J Biol Chem, 276, 30245, 10.1074/jbc.M102174200 Han, 2012, GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy, Cardiovasc Res, 93, 645, 10.1093/cvr/cvs001 Hori, 2009, Oxidative stress and left ventricular remodelling after myocardial infarction, Cardiovasc Res, 81, 457, 10.1093/cvr/cvn335 Suh, 2012, Up-regulation of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes by repressing GSK-3beta protein expression, Biochem Biophys Res Commun, 423, 404, 10.1016/j.bbrc.2012.05.138 Nattel, 2002, New ideas about atrial fibrillation 50 years on, Nature, 415, 219, 10.1038/415219a Nattel, 2007, Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation, Physiol Rev, 87, 425, 10.1152/physrev.00014.2006 Atienza, 2006, Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant mechanism, Circulation, 114, 2434, 10.1161/CIRCULATIONAHA.106.633735 Bosch, 1999, Ionic mechanisms of electrical remodeling in human atrial fibrillation, Cardiovasc Res, 44, 121, 10.1016/S0008-6363(99)00178-9 Cha, 2004, Atrial ionic remodeling induced by atrial tachycardia in the presence of congestive heart failure, Circulation, 110, 1520, 10.1161/01.CIR.0000142052.03565.87 Dobrev, 2002, Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation, Cardiovasc Res, 54, 397, 10.1016/S0008-6363(01)00555-7 Gaborit, 2005, Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation, Circulation, 112, 471, 10.1161/CIRCULATIONAHA.104.506857 Workman, 2001, The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation, Cardiovasc Res, 52, 226, 10.1016/S0008-6363(01)00380-7 Zhang, 2005, Role of up-regulation of IK1 in action potential shortening associated with atrial fibrillation in humans, Cardiovasc Res, 66, 493, 10.1016/j.cardiores.2005.01.020 Luo, 2013, MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation, J Clin Invest, 123, 1939, 10.1172/JCI62185 Curci, 2009, Digging in the soil of the aorta to understand the growth of abdominal aortic aneurysms, Vascular, 17, S21, 10.2310/6670.2008.00085 Gomez, 2012, Smooth muscle cell phenotypic switching in atherosclerosis, Cardiovasc Res, 95, 156, 10.1093/cvr/cvs115 Nguyen, 2013, Smooth muscle cell plasticity: fact or fiction?, Circ Res, 112, 17, 10.1161/CIRCRESAHA.112.281048 Owens, 2004, Molecular regulation of vascular smooth muscle cell differentiation in development and disease, Physiol Rev, 84, 767, 10.1152/physrev.00041.2003 Wan, 2012, Vein graft failure: current clinical practice and potential for gene therapeutics, Gene Ther, 19, 630, 10.1038/gt.2012.29 Rensen, 2007, Regulation and characteristics of vascular smooth muscle cell phenotypic diversity, Neth Heart J, 15, 100, 10.1007/BF03085963 Leeper, 2011, MicroRNA-26a is a novel regulator of vascular smooth muscle cell function, J Cell Physiol, 226, 1035, 10.1002/jcp.22422 Leeper, 2011, MicroRNA and mechanisms of impaired angiogenesis in diabetes mellitus, Circulation, 123, 236, 10.1161/CIRCULATIONAHA.110.003855 Shieh, 2011, Elevated miR-499 levels blunt the cardiac stress response, PLoS One, 6, e19481, 10.1371/journal.pone.0019481 Divakaran, 2008, The emerging role of microRNAs in cardiac remodeling and heart failure, Circ Res, 103, 1072, 10.1161/CIRCRESAHA.108.183087 Leask, 2004, TGF-beta signaling and the fibrotic response, FASEB J, 18, 816, 10.1096/fj.03-1273rev Weber, 1991, Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system, Circulation, 83, 1849, 10.1161/01.CIR.83.6.1849 Kumar, 2011, Inhibition of nuclear factor kappaB regresses cardiac hypertrophy by modulating the expression of extracellular matrix and adhesion molecules, Free Radic Biol Med, 50, 206, 10.1016/j.freeradbiomed.2010.10.711 Adam, 2012, Role of miR-21 in the pathogenesis of atrial fibrosis, Basic Res Cardiol, 107, 278, 10.1007/s00395-012-0278-0 Castoldi, 2012, MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension, J Cell Physiol, 227, 850, 10.1002/jcp.22939 Thum, 2012, Cardiac fibrosis revisited by microRNA therapeutics, Circulation, 126, 800, 10.1161/CIRCULATIONAHA.112.125013 Wang, 2014, MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart, PLoS One, 9, e84188, 10.1371/journal.pone.0084188 Nigam, 2010, Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves, J Heart Valve Dis, 19, 459 Kota, 2009, Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model, Cell, 137, 1005, 10.1016/j.cell.2009.04.021 Sun, 2012, MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation, J Clin Invest, 122, 1973 Sun, 2014, Role of miR-181 family in regulating vascular inflammation and immunity, Trends Cardiovasc Med, 24, 105, 10.1016/j.tcm.2013.09.002 Anand, 2010, MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis, Nat Med, 16, 909, 10.1038/nm.2186 Babar, 2012, Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma, Proc Natl Acad Sci U S A, 109, E1695, 10.1073/pnas.1201516109